Study S003247

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerance, PK and PD Parameters of Single Dose Escalation of GZR33 and Single Administration of GZR101 in Healthy Male Adult Subjects

ClinicalTrials.gov record

Registration

Registration: NCT06548932
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 52
Start: 2022-06-30
Primary completion: 2023-02-24
Lead sponsor: Gan and Lee Pharmaceuticals, USA
Conditions: Healthy Subjects
Interventions: DRUG:GZR33 Injection; DRUG:GZR101 Injection; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Incidence of adverse events (AE) [From Predose to Day14 after a single dose]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.